RVTY vs. BIO.B, AVTR, WAT, TXG, ILMN, INCY, KRTX, CRL, MEDP, and NBIX
Should you be buying Revvity stock or one of its competitors? The main competitors of Revvity include Bio-Rad Laboratories (BIO.B), Avantor (AVTR), Waters (WAT), 10x Genomics (TXG), Illumina (ILMN), Incyte (INCY), Karuna Therapeutics (KRTX), Charles River Laboratories International (CRL), Medpace (MEDP), and Neurocrine Biosciences (NBIX). These companies are all part of the "medical" sector.
Revvity (NYSE:RVTY) and Bio-Rad Laboratories (NYSE:BIO.B) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, community ranking, earnings, profitability, risk, media sentiment and valuation.
Revvity has a net margin of 25.20% compared to Bio-Rad Laboratories' net margin of -23.86%. Revvity's return on equity of 7.41% beat Bio-Rad Laboratories' return on equity.
Revvity currently has a consensus price target of $118.91, indicating a potential upside of 13.25%. Given Revvity's higher probable upside, equities research analysts plainly believe Revvity is more favorable than Bio-Rad Laboratories.
In the previous week, Revvity had 4 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 5 mentions for Revvity and 1 mentions for Bio-Rad Laboratories. Revvity's average media sentiment score of 0.89 beat Bio-Rad Laboratories' score of -0.36 indicating that Revvity is being referred to more favorably in the media.
Revvity has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500.
86.7% of Revvity shares are owned by institutional investors. Comparatively, 0.0% of Bio-Rad Laboratories shares are owned by institutional investors. 0.6% of Revvity shares are owned by company insiders. Comparatively, 28.4% of Bio-Rad Laboratories shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Bio-Rad Laboratories received 115 more outperform votes than Revvity when rated by MarketBeat users. Likewise, 57.60% of users gave Bio-Rad Laboratories an outperform vote while only 50.00% of users gave Revvity an outperform vote.
Revvity has higher revenue and earnings than Bio-Rad Laboratories. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.
Summary
Revvity beats Bio-Rad Laboratories on 14 of the 17 factors compared between the two stocks.
Get Revvity News Delivered to You Automatically
Sign up to receive the latest news and ratings for RVTY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RVTY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools